Primrose Bio's AI-Driven Quest to Upgrade the Code of Genetic Medicine

SAN DIEGO, CA – July 15, 2026 – In the rapidly expanding universe of genetic medicine, the core challenge is often one of control. It’s not enough to deliver a therapeutic gene to a cell; you have to ensure it turns on, produces the right amount of protein, and stays active long enough to have a meaningful effect. Today, San Diego-based Primrose Bio, Inc. announced a significant step toward mastering that control, securing a $2 million federal grant to develop a new class of drug design tools.

This isn't just another funding announcement. The Direct-to-Phase II Small Business Innovation Research (SBIR) award from the National Institutes of Health (NIH) is a high-level endorsement of Primrose Bio's strategy to solve a fundamental bottleneck in DNA and RNA therapies. The company is developing synthetic genetic “switches” designed to boost and prolong the activity of these advanced medicines, a move that could enhance the efficacy of everything from cancer immunotherapies to vaccines and treatments for rare diseases.

The Genetic Control Room

For decades, the 99% of our DNA that doesn't directly code for proteins was famously dismissed as “junk.” We now know this noncoding DNA is anything but. It is the cell’s master control room, a vast and complex network of regulatory elements—promoters, enhancers, and silencers—that dictate which genes are switched on or off, in which cells, and for how long. This intricate system is what allows a heart cell and a brain cell to have identical DNA but perform wildly different functions.

Genetic medicines, which work by instructing our cells to produce therapeutic proteins, are critically dependent on these regulatory signals. A key limitation for many of these therapies is achieving robust and sustained protein expression. Too little protein and the treatment is ineffective; too short a duration and the patient requires frequent, costly re-dosing. Primrose Bio aims to solve this by engineering its own high-performance regulatory elements from scratch.

“Noncoding sequences are critical control points for protein expression,” said Patrik Engström, Ph.D., the project’s Principal Investigator and a Principal Scientist at Primrose Bio. “Our platform can evaluate billions of candidates and identify those with the greatest potential. This funding will help us optimize and validate them for therapeutic use.” The goal is to create licensable genetic components that drug developers can plug into their DNA or RNA constructs to act as powerful amplifiers and timers, ensuring a therapeutic gene performs its job with unprecedented efficiency.

An AI-Powered Search for the Golden Sequence

Identifying the perfect noncoding sequence to drive therapeutic expression is a monumental task. The number of potential genetic combinations is astronomically large, far beyond the scope of traditional trial-and-error research. This is where Primrose Bio’s technological platform provides a decisive edge. The company is deploying an ultra-high-throughput system capable of screening billions of synthetic DNA sequences simultaneously.

This brute-force screening is guided by a sophisticated layer of artificial intelligence. The company’s proprietary AI algorithms are designed to sift through the massive datasets generated by the screening process, identifying subtle patterns and non-obvious relationships that correlate with optimal protein expression. By learning from each cycle, the AI can then predict and design new, even more effective sequences. This convergence of synthetic biology and AI is at the vanguard of modern drug discovery, enabling researchers to engineer biological functions with a level of precision previously unimaginable.

This AI-driven approach allows Primrose Bio to move beyond naturally occurring sequences and into the realm of purely synthetic design. It's not just about finding the best existing switch; it's about building a better one. This capability to design, build, and test on a massive scale is what sets the project apart and captures the essence of the NIH’s investment in high-impact innovation.

From Lab Feasibility to Commercial Enabler

The structure of the NIH award itself speaks volumes. A Direct-to-Phase II SBIR grant is reserved for projects that have already demonstrated strong technical merit and feasibility, allowing them to bypass the initial proof-of-concept phase. This signifies that the NIH’s National Center for Advancing Translational Sciences (NCATS) sees Primrose Bio’s technology as not just promising, but mature and on a clear path toward commercial application.

This confidence is built on the company's established track record. Primrose Bio is not a speculative startup; it is a seasoned technology provider with a portfolio of commercially validated systems. Its flagship Pfenex Expression Technology®, a microbial production platform, is already used in six products approved by global regulators, including Rylaze®, marketed by Jazz Pharmaceuticals for treating leukemia, and a teriparatide injection launched by Alvogen. These successes, along with partnerships with giants like Merck and the Serum Institute of India, prove the company’s ability to deliver robust, scalable solutions that solve real-world manufacturing challenges.

“This award builds on Primrose Bio's track record of bringing enabling technologies into commercial use,” said CEO Drew Burch. “It expands the sequence-based tools we can offer partners to improve the performance of genetic medicines.” This positions the company less as a direct drug developer and more as a crucial enabler for the entire genetic medicine industry. By creating licensable sequence elements, Primrose Bio provides the picks and shovels for the gold rush in DNA and RNA therapeutics, allowing other companies to make their novel drugs more effective.

The Patient Horizon: More Potent and Durable Therapies

Ultimately, the value of this technology will be measured by its impact on patients. Enhanced and prolonged protein expression could fundamentally change the treatment paradigm for a host of devastating diseases. For rare genetic disorders caused by a missing or faulty protein, a therapy that ensures sustained production could mean the difference between managing symptoms and a functional cure. In oncology, it could make cell therapies like CAR-T more persistent in hunting down and destroying cancer cells.

In the field of infectious diseases, the implications are equally profound. The success of mRNA vaccines hinged on their ability to prompt cells to produce a viral protein and trigger an immune response. A technology that makes that protein expression stronger and longer-lasting could lead to more effective vaccines that require fewer doses. The global genomic medicine market, projected to exceed $118 billion by 2032, is driven by the pursuit of such breakthroughs.

By tackling the foundational mechanics of gene expression, Primrose Bio's NIH-funded project represents a critical investment in the infrastructure of tomorrow's medicine. The grant provides the fuel, but the engine is a powerful combination of proven manufacturing expertise and cutting-edge AI-driven design. This work could soon provide drug developers with a new set of rules for writing the code of life, leading to a new generation of more potent, durable, and life-changing genetic therapies.